Telesis Bio (NASDAQ:TBIO) Shares Scheduled to Reverse Split on Thursday, May 9th

Telesis Bio, Inc. (NASDAQ:TBIO)’s stock is going to reverse split before the market opens on Thursday, May 9th. The 1-18 reverse split was announced on Thursday, May 9th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, May 9th.

Telesis Bio Trading Down 10.0 %

TBIO traded down $0.03 during trading hours on Tuesday, reaching $0.31. The company’s stock had a trading volume of 808,045 shares, compared to its average volume of 575,848. The stock has a market cap of $9.21 million, a PE ratio of -0.19 and a beta of 1.93. Telesis Bio has a fifty-two week low of $0.28 and a fifty-two week high of $3.01. The company has a debt-to-equity ratio of 22.76, a current ratio of 3.71 and a quick ratio of 3.22. The business’s 50-day moving average is $0.44 and its 200-day moving average is $0.45.

Telesis Bio (NASDAQ:TBIO) last issued its quarterly earnings data on Thursday, March 28th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. The firm had revenue of $6.98 million for the quarter. Telesis Bio had a negative net margin of 173.78% and a negative return on equity of 176.47%.

Telesis Bio Company Profile

Telesis Bio, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system, that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits which contains the necessary building blocks and reagents, including proprietary gibson assembly branded reagents, for specific synthetic biology workflow applications.